Bellevue Group AG Buys 33,100 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Bellevue Group AG raised its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 129.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,729 shares of the company's stock after acquiring an additional 33,100 shares during the quarter. Bellevue Group AG owned about 0.06% of BeiGene worth $13,185,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Portland Investment Counsel Inc. boosted its position in shares of BeiGene by 50.0% during the 3rd quarter. Portland Investment Counsel Inc. now owns 3,000 shares of the company's stock valued at $674,000 after purchasing an additional 1,000 shares in the last quarter. Verition Fund Management LLC acquired a new position in BeiGene in the third quarter valued at approximately $281,000. Capstone Investment Advisors LLC bought a new position in shares of BeiGene during the 3rd quarter worth approximately $1,192,000. Walleye Capital LLC grew its position in shares of BeiGene by 50.1% during the 3rd quarter. Walleye Capital LLC now owns 26,721 shares of the company's stock worth $5,999,000 after buying an additional 8,924 shares during the period. Finally, FMR LLC increased its stake in shares of BeiGene by 0.8% in the 3rd quarter. FMR LLC now owns 1,660,011 shares of the company's stock valued at $372,689,000 after acquiring an additional 12,855 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the company's stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. Insiders sold a total of 63,538 shares of company stock valued at $12,594,017 in the last ninety days. 7.43% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on BGNE. Citigroup raised their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. JPMorgan Chase & Co. upped their price target on BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 22nd. StockNews.com cut BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. TD Cowen upped their target price on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Finally, JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, BeiGene has a consensus rating of "Moderate Buy" and an average price target of $247.07.

BeiGene Stock Up 4.3 %

BeiGene stock traded up $8.84 during midday trading on Friday, hitting $215.00. 258,633 shares of the stock were exchanged, compared to its average volume of 285,123. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $248.16. The business's 50-day moving average price is $212.42 and its 200-day moving average price is $184.63.

BeiGene (NASDAQ:BGNE - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business's revenue was up 28.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 earnings per share. Sell-side analysts predict that BeiGene, Ltd. will post -5.38 EPS for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.